



FOR IMMEDIATE RELEASE

Media Contact:

Russo Partners, LLC
Tony Russo, Ph.D., or Andreas Marathovouniotis
212-845-4251 or 212-845-5235
tony.russo@russopartnersllc.com
andreas.marathis@russopartnersllc.com

TetraLogic Pharmaceuticals
James Goldschmidt, Ph.D.
610-889-9900

TetraLogic Appoints Jonathan B. Lloyd Jones as Chief Financial Officer and Vice President Corporate Development

MALVERN, Pa., June 8, 2011 – TetraLogic Pharmaceuticals, a biopharmaceutical company developing novel small molecule Smac mimetic drugs to treat cancer, today announced the appointment of Mr. Jonathan B. Lloyd Jones, ACA, MBA, as chief financial officer and vice president of corporate development.

Mr. Lloyd Jones joins TetraLogic with over 25 years of corporate development and finance experience. He has led negotiations, valuation and diligence teams that developed and executed over \$2 billion of biotechnology and pharmaceutical company mergers and acquisitions, financing and licensing transactions. At TetraLogic, Mr. Lloyd Jones will lead the company's corporate development and financing strategies as well as the negotiation and execution of related transactions.

From 2006 to 2010, Mr. Lloyd Jones served as vice president of finance at TransMolecular, Inc. During the prior 10 years, he was employed by Genzyme as a senior director of corporate development. Earlier in his career Mr. Lloyd Jones was employed by the Royal Bank of Scotland (Nassau). Mr. Lloyd Jones holds a master of business administration from The Wharton School of the University of Pennsylvania and is a member of the Institute of Chartered Accountants in England & Wales.

About TetraLogic Pharmaceuticals

TetraLogic Pharmaceuticals is a privately held biopharmaceutical company that focuses on the discovery and development of Smac mimetics, small molecule drugs that mimic Smac (Second mitochondrial-derived activator of caspases) for the treatment of cancers. The company's institutional investors include Clarus Ventures, HealthCare Ventures, Quaker BioVentures, Novitas Capital, Nextech Invest Ltd, Hatteras Venture Partners, Pfizer Ventures, Latterell Venture Partners, the Vertical Group, Amgen Ventures, and Kammerer Associates. For additional information, please refer to the company's Web site at www.tetralogicpharma.com.